ArticleJournal of cellular and molecular medicine2025
A Pan-Cancer Study of Tumour-Associated Efferocytosis Core Genes and Preliminary Exploration of TIMD4 in Renal Cell Carcinoma.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrating spatial and single-cell transcriptomics via machine learning to characterize efferocytosis in hepatocellular carcinoma prognosis and immunotherapy.Translational oncology · 2026Article
- Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy.Molecular cancer · 2025Review
- Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A Pan-Cancer Study of Tumour-Associated Efferocytosis Core Genes and Preliminary Exploration of TIMD4 in Renal Cell Carcinoma.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Efferocytosis plays a crucial role in maintaining the stability of the immune microenvironment. Increasing research indicates that efferocytosis core genes (ECGs) are not only widely expressed in immune cells, but also expressed at significant levels in tumour cells, impacting tumour progression. However, the comprehensive effects of ECGs on cancer prognosis and the immune microenvironment remain underexplored. This study analysed data from 33 tumour types to assess the expression, diagnostic and prognostic values of ECGs as well as gene modification landscapes. It also predicted the correlation between ECGs, the immune microenvironment and responses to immunotherapy, revealing that lower ECGs expression levels were associated with better immunotherapy responses in various cancers. Additionally, molecular docking studies simulated the interactions between TIMD4 and its sensitive drugs, facilitating targeted drug development. Finally, both in vitro and in vivo experiments confirmed that silencing TIMD4 could effectively inhibit the proliferation and invasion of renal cell carcinoma. Overall, TIMD4 can be used as an important biomarker for tumour prognosis and immunotherapy response, providing new insights into the mechanisms of tumour immune microenvironment and progression, as well as a novel therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.